Hans Wigzell
Chairman of Corporate Strategy Board & Independent Non-Employee DirectorProf. Hans Wigzell, M.D., Ph.D. serves as Independent Chairman of the Board of RaySearch Laboratories AB (publ) since October 2022. He also served as an Independent Director from 2004. He joined the firm in May 2004. He is Co-Founder of Affibody Medical AB (publ), which he co-founded in 1998, and also serves as Member of its Scientific Advisory Board since 2002. He is Founder of Parallel Solutions, Inc. Prof. Wigzell serves as Chairman of the Board at ExThera AB and Rhenman & Partners Asset Management AB. He serves as Chairman of the Corporate Strategy Board & Independent Non-Employee Director of Sarepta Therapeutics, Inc. (formerly, AVI Biopharma, Inc.) since June 2010 and as Chairman of the Scientific Advisory Board of Swedish Orphan Biovitrum AB (publ), which he joined in 2001. His other current roles include Scientific Consultant at Ixion Biotechnology, Inc.; Board Member of Valneva SA, Humalabs LLC, SBL Vaccin, Karolinska Development (Sweden), Raysearch AB (Sweden), and Intercell (Austria); Director at Raysearch Medical AB since May 2004; Director and Head of Centre for Medical Innovations at Karolinska Institutet; Senior Scientific Advisor for HB M Partners (Switzerland); and Chief Scientific Advisor to the Swedish Prime Minister. He also serves on the Scientific Advisory Boards of Apogee Technology, Inc. since October 2007, Cognito Therapeutics, Inc. since October 2025, BioArctic AB (publ), Epiphany Biosciences, Inc., Probi AB (publ), InDex Pharmaceuticals AB, InDex Pharmaceuticals Hldg AB, and HBM BioVentures AG, and on the Advisory Board of HBM Healthcare Investments AG. Previously, Prof. Wigzell served as Chairman of KDventures AB from May 16, 2024 to December 2024. He joined KDventures AB in 2006. During his tenure at Diamyd Medical AB (publ) from 1996 to December 2018, he served as a Member of the Scientific Advisory Board. He served as a Member of the Supervisory Board at Valneva SE from March 7, 2013 to June 30, 2016 and as an Independent Director at Swedish Orphan Biovitrum AB from 2005 to May 26, 2016. At KDventures AB, he also served as an Independent Director in August 2020, as Independent Chairman from December 2017 to August 2020, as Chairman from 2006 to September 30, 2013, as a Member of the Investment Advisory Board until August 2011, and as Senior Strategic Advisor. He served as a Director at Probi AB (publ) from 2007 to April 2010. He served as a Member of the Supervisory Board since May 12, 2006 and as a Member of the Scientific Advisory Board since February 2006 at Intercell AG. He also served as a Member of the Scientific Advisory Board at CASI Pharmaceuticals, Inc. since July 2006 and as a Member of the Scientific and Medical Advisory Board at Mertiva AB (publ), which he joined in 2006. From 1999 to 2007, he served as the Chief Scientific Advisor and Senior Scientific Advisor to the Swedish Government. His other prior roles include President and Dean/Professor Emeritus of Immunology at Karolinska Institutet from 1995 to 2003, Secretary General at Swedish Institute for Infectious Disease Control since 1993, and Director General and President at the National Bacteriological Laboratory from 1988 to 1992. He was a Professor in the department of Immunology at Uppsala University Medical School and joined Karolinska Institutet as Acting Associate Professor in the department of tumor biology in 1971. He also served as Director General of the Smittskyddsinstitutet, Director of NeoDynamics AB (publ), Director of SOBI AB, Deputy Chairman and Chairman of the Scientific Advisory Board of KI Management AB, and Special Cancer Scientist at Swedish Cancer Society. He served on the Scientific Advisory Boards of Biocon Limited, Flerie AB, KDev Exploratory AB, and InDex Pharmaceuticals Holding AB (publ), and as a Scientific Advisor at Ixion Biotechnology, Inc. and a Member of the Institutional Advisory Board at VIB BV. He was appointed as one of the 11 Advisors to the EU Commissioner for research on life science issues. He was elected as the Chairman of the EU Concerted Research Program into AIDS vaccination in 1990, was appointed as the Chairman of the Nobel Assembly in 2000, and as the Chairman for the WHO-UNAIDS Vaccine Advisory Committee in 2002. Prof. Wigzell has published numerous scientific articles in international magazines and has been awarded a number of prizes including the Anders Jahre Medical Prize in 1975, the Erik Fernström's Prize for Young Scientists in 1979, the Russel Weiser Lecturer Prize, and the Smith Lecture Award. Prof. Wigzell holds an M.D., a Ph.D., and an Sc.D. in 1967 from Karolinska Institutet. He also holds an Honorary Doctorate from Turun yliopisto and an Honorary Doctorate from Universita' degli Studi di Roma - Tor Vergata.
Positions
- Company NameSarepta Therapeutics, Inc.Stock CodeSRPTPositionChairman of Corporate Strategy Board & Independent Non-Employee DirectorColleagues
- IMIan Michael EstepanPresident & COO
- MKM. Kathleen Behrens WilseyIndependent Chairwoman
- RHRyan H. WongExecutive VP & CFO
- CLCristin L. RothfussExecutive VP, General Counsel & Company Secretary
- DSDouglas S. IngramAdvisor
- LRLouise R. Rodino-KlapacPresident of Research & Development and Technical Operations
- MEMichael E. SeverinoCEO & Director
- RJRichard Jon BarryIndependent Director
- DPDeirdre P. ConnellyIndependent Director
